Zobrazeno 1 - 10
of 21
pro vyhledávání: '"John Hainsworth"'
Autor:
David B. Agus, Iain J. Webb, Yuanjun Shi, Mitchell E. Gross, John Hainsworth, Omid Hamid, Gary R. MacVicar, Lowell Hart, Daniel Shevrin, Walter M. Stadler, Ajit Suri, David MacLean, Robert Dreicer
Purpose: The androgen receptor pathway remains active in men with prostate cancer whose disease has progressed following surgical or medical castration. Orteronel (TAK-700) is an investigational, oral, nonsteroidal, selective, reversible inhibitor of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b8e4b1833b7f3adbaa2d02c839a5788
https://doi.org/10.1158/1078-0432.c.6521592
https://doi.org/10.1158/1078-0432.c.6521592
Autor:
David B. Agus, Iain J. Webb, Yuanjun Shi, Mitchell E. Gross, John Hainsworth, Omid Hamid, Gary R. MacVicar, Lowell Hart, Daniel Shevrin, Walter M. Stadler, Ajit Suri, David MacLean, Robert Dreicer
PDF file - 65K, Schedule of assessments.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64346251ea584c498f27c381ff4abcc0
https://doi.org/10.1158/1078-0432.22449246.v1
https://doi.org/10.1158/1078-0432.22449246.v1
Autor:
Arlene O Siefker-Radtke, Andrea Necchi, Se Hoon Park, Jesús García-Donas, Robert A Huddart, Earle F Burgess, Mark T Fleming, Arash Rezazadeh Kalebasty, Begoña Mellado, Sergei Varlamov, Monika Joshi, Ignacio Duran, Scott T Tagawa, Yousef Zakharia, Sydney Akapame, Ademi E Santiago-Walker, Manish Monga, Anne O'Hagan, Yohann Loriot, Scott Tagawa, Aude Flechon, Boris Alexeev, Sergey Varlamov, Robert Huddart, Earle Burgess, Arash Rezazadeh, Arlene Siefker-Radtke, Yann Vano, Donatello Gasparro, Alketa Hamzaj, Eugeniy Kopyltsov, Jesus Gracia Donas, Begona Mellado, Omi Parikh, Peter Schatteman, Stephane Culine, Nadine Houédé, Sylvie Zanetta, Gaetano Facchini, Giorgio Scagliotti, Giovanni Schinzari, Jae Lyun Lee, Mikhail Shkolnik, Mark Fleming, Monica Joshi, Peter O'Donnell, Herbert Stöger, Karel Decaestecker, Luc Dirix, Jean Pascal Machiels, Dephine Borchiellini, Remy Delva, Frederic Rolland, Boris Hadaschik, Margitta Retz, Eli Rosenbaum, Umberto Basso, Alessandra Mosca, Hyo Jin Lee, Dong Bok Shin, Cristina Cebotaru, Victor Moreno, Jose Luis Perez Gracia, Alvaro Pinto, Wen-Pin Su, Shian-Shiang Wang, John Hainsworth, Ian Schnadig, Sandhya Srinivas, Nicholas Vogelzang, Wolfgang Loidl, Johannes Meran, Marine Gross Goupil, Florence Joly, Florian Imkamp, Theodor Klotz, Susanne Krege, Matthias May, Wolfgang Schultze-Seemann, Arne Strauss, Uwe Zimmermann, Daniel Keizman, Avivit Peer, Avishai Sella, Rossana Berardi, Ugo De Giorgi, Cora Nanette Sternberg, Sun Young Rha, Iurie Bulat, Adel Izmailov, Vsevolod Matveev, Vladimir Vladimirov, Joan Carles, Albert Font, Maribel Saez, Isabel Syndikus, Kathryn Tarver, Leonard Appleman, John Burke, Nancy Dawson, Sharad Jain
Publikováno v:
The Lancet Oncology, Vol. 23, no.2, p. 248-258 (2022)
Background Erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, was shown to be clinically active and tolerable in patients with advanced urothelial carcinoma and prespecified FGFR alterations in the primary analysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f518baf9decca47c67f21a5a6035817d
https://hdl.handle.net/2078.1/275404
https://hdl.handle.net/2078.1/275404
Autor:
Charles Swanton, Claire F. Friedman, Christopher J. Sweeney, Funda Meric-Bernstam, David Spigel, Ron Bose, Howard Burris, Walter C. Darbonne, Julia Malato, Jonathan Levy, Yong Wang, Tania Szado, Katja Schulze, John Hainsworth, Razelle Kurzrock
Publikováno v:
Cancer Research. 82:CT032-CT032
Purpose: Alectinib is FDA-approved for ALK-positive, metastatic non-small cell lung cancer (NSCLC). We analyzed alectinib treatment in a pan-tumor population with ALK alterations from MyPathway (NCT02091141), a multi-basket study assessing approved t
Autor:
Denise Yardley, Karyn Dyehouse, Aruna Mani, Carmen Calfa, David Drosick, Kathleen Yost, Diana Shipley, Raven Quinn, Robyn Young, Lindsey Finney, Chris Earwood, Mythili Shastry, John Hainsworth
Publikováno v:
Cancer Research. 75:P3-11
Background: Pathologic complete response (pCR) following neoadjuvant chemotherapy for locally advanced breast cancer strongly correlates with improved disease-free survival, rates of breast-conserving surgery, and provides an early indicator of treat
Autor:
Daniel P Petrylak, Ronald de Wit, Kim N Chi, Alexandra Drakaki, Cora N Sternberg, Hiroyuki Nishiyama, Daniel Castellano, Syed Hussain, Aude Fléchon, Aristotelis Bamias, Evan Y Yu, Michiel S van der Heijden, Nobuaki Matsubara, Boris Alekseev, Andrea Necchi, Lajos Géczi, Yen-Chuan Ou, Hasan Senol Coskun, Wen-Pin Su, Miriam Hegemann, Ivor J Percent, Jae-Lyun Lee, Marcello Tucci, Andrey Semenov, Fredrik Laestadius, Avivit Peer, Giampaolo Tortora, Sufia Safina, Xavier Garcia del Muro, Alejo Rodriguez-Vida, Irfan Cicin, Hakan Harputluoglu, Ryan C Widau, Astra M Liepa, Richard A Walgren, Oday Hamid, Annamaria H Zimmermann, Katherine M Bell-McGuinn, Thomas Powles, Suet-Lai Shirley Wong, Thean Hsiang Tan, Elizabeth Jane Hovey, Timothy Dudley Clay, Siobhan Su Wan Ng, Annemie Rutten, Jean-Pascal Machiels, Herlinde Dumez, Susanna Yee-Shan Cheng, Kim Nguyen Chi, Cristiano Ferrario, Lisa Sengeloev, Niels Viggo Jensen, Constance Thibault, Brigitte Laguerre, Florence Joly, Aude Flechon, Stéphane Culine, Catherine Becht, Günter Niegisch, Michael Stöckle, Marc-Oliver Grimm, Georgios Gakis, Wolfgang Schultze-Seemann, Haralambos Kalofonos, Dimitrios Mavroudis, Christos Papandreou, Vasilis Karavasilis, Janos Révész, Lajos Geczi, Eli Rosenbaum, Raya Leibowitz-Amit, Daniel Kejzman, David Sarid, Giorgio Vittorio Scagliotti, Sergio Bracarda, Francesco Massari, Takahiro Osawa, Naoto Miyajima, Nobuo Shinohara, Fumimasa Fukuta, Chikara Ohyama, Wataru Obara, Shinichi Yamashita, Yoshihiko Tomita, Koji Kawai, Satoshi Fukasawa, Masafumi Oyama, Junji Yonese, Masayoshi Nagata, Motohide Uemura, Kazuo Nishimura, Mutsushi Kawakita, Hiroyuki Tsunemori, Katsuyoshi Hashine, Junichi Inokuchi, Akira Yokomizo, Satoshi Nagamori, Hyo Jin Lee, Se Hoon Park, Sun Young Rha, Yu Jung Kim, Yun-Gyoo Lee, Leticia Vazquez Cortés, Claudia Lorena Urzua Flores, Reinoud J B Blaisse, Fransiscus L G Erdkamp, Maureen J B Aarts, Joanna Wojcik-Tomaszewska, Piotr Tomczak, Bozena Sikora-Kupis, Michael Schenker, Alina Amalia Herzal, Anghel Adrian Udrea, Petr Karlov, Sufia Z Safina, Roman Fomkin, Enrique Grande Pulido, F Xavier García Del Muro, Juan Ignacio Delgado Mignorance, Daniel Castellano Gauna, Alejo Rodríguez-Vida, Yu-Li Su, Chien-Liang Lin, Chia-Chi Lin, Su-Peng Yeh, Irfan Çiçin, Mustafa Erman, Yuksel Urun, Yurii Golovko, Igor Bondarenko, Ivan Sinielnikov, Simon Crabb, Isabel Syndikus, Robert Huddart, Santhanam Sundar, Simon Chowdhury, Naveed Sarwar, Thomas Flaig, Chong Xian Pan, Daniel Petrylak, James Schwarz, Ivor Percent, Jennifer Cultrera, John Hainsworth, Benjamin Herms, William Lawler, Thomas Lowe, Scott Tagawa, Jeanny Aragon-Ching, Ulka Vaishampayan
Publikováno v:
Lancet (London, England), Vol. 390, no.10109, p. 2266-2277 (2017)
Lancet, 390(10109), 2266-2277. Elsevier Science
Lancet (UK), 390(10109), 2266-2277. Elsevier Ltd.
Lancet, 390(10109), 2266-2277. Elsevier Science
Lancet (UK), 390(10109), 2266-2277. Elsevier Ltd.
Summary Background Few treatments with a distinct mechanism of action are available for patients with platinum-refractory advanced or metastatic urothelial carcinoma. We assessed the efficacy and safety of treatment with docetaxel plus either ramucir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1d65e42b670b576f5a3f43b55580726
https://hdl.handle.net/2078.1/275434
https://hdl.handle.net/2078.1/275434
Autor:
John R, Mackey, Miguel, Martin, Tadeusz, Pienkowski, Janusz, Rolski, Jean-Paul, Guastalla, Amer, Sami, John, Glaspy, Eva, Juhos, Andrew, Wardley, Tommy, Fornander, John, Hainsworth, Robert, Coleman, Manuel R, Modiano, Jeferson, Vinholes, Tamas, Pinter, Alvaro, Rodríguez-Lescure, Bruce, Colwell, Pierre, Whitlock, Louise, Provencher, Kara, Laing, David, Walde, Chris, Price, Judith C, Hugh, Barrett H, Childs, Kimberly, Bassi, Mary-Ann, Lindsay, Véronique, Wilson, Matthieu, Rupin, Vincent, Houé, Charles, Vogel, L, Campos
Publikováno v:
The Lancet Oncology. 14:72-80
Summary Background We compared standard adjuvant anthracycline chemotherapy with anthracycline–taxane combination chemotherapy in women with operable node-positive breast cancer. Here we report the final, 10-year follow-up analysis of disease-free
Autor:
Quentin Jones, Loren Terveen, Bonnie Nardi, Steve Whittaker, John Hainsworth, Ellen Isaacs, Mike Creech
Publikováno v:
ACM Transactions on Computer-Human Interaction. 11:445-471
Modern work is a highly social process, offering many cues for people to organize communication and access information. Shared physical workplaces provide natural support for tasks such as (a) social reminding about communication commitments and keep
Publikováno v:
Anti-Cancer Drugs. 14:S13-S19
Background Non-small cell lung cancer (NSCLC), ovarian and breast cancers, especially in advanced stages, are difficult to treat using chemotherapy, and novel treatments are required to improve the outcome for the large numbers of patients who relaps
Publikováno v:
Communications of the ACM. 45:89-95
Visualizing personal social networks, the system allows users to model and arrange their own in maps of individual contacts and groups, along with the relationships among them.